Kringle Pharma (4884) · PolicyRestated
Bringing products to society through in-house development and regulatory approval applications
First written in FY2020. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Commercializing Pharmaceuticals Through In-House Development and Marketing Approval ApplicationsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「With rare diseases as the primary target, our basic policy is to develop products in-house and obtain marketing approval ourselves so that the results of clinical trials can be brought to society as pharmaceuticals with greater certainty.」
The company has reiterated its policy of in-house development and obtaining marketing approval for treatments targeting rare diseases. - FY2020First statedAnnual report
「To ensure that the results of clinical trials are brought to society as pharmaceuticals, we will make it our basic policy to develop products in-house and obtain marketing approval for them ourselves.」
The company’s policy is to pursue development and marketing approval applications in-house rather than primarily licensing products to external pharmaceutical companies.